Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
20 October 2020

ORYZON holds its 4th annual Solidarity Day

15 October 2020

ORYZON publishes paper in Journal of Clinical Oncology demonstrating relevance of iadademstat in leukemia

17 September 2020

ORYZON presents efficacy and safety results of its CLEPSIDRA trial with iadademstat in ED-SCLC patients at ESMO-2020

21-24 September 2020

Sachs 20th Annual Biotech in Europe Forum

16-21 September 2020

ESMO Virtual Congress 2020

14-16 September 2020

H.C. Wainwright 22nd Annual Global Investment Conference

8 September 2020

ORYZON to present at upcoming international conferences

2 September 2020

Annual General Shareholders Meeting 2020

27 July 2020

ORYZON presents vafidemstat clinical data from its Phase IIa clinical trial ETHERAL in Alzheimer’s at the virtual AAIC-2020 conference

22 July 2020

ORYZON First Half Ended June 30, 2020 Results and Corporate Update

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Current page 32
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel